4569.T
Latest Trade
1,912.00JPYChange
-4.00(-0.21%)Volume
151,400Today's Range
-
1,946.0052 Week Range
-
2,754.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 1,916.00 |
|---|---|
Open | 1,921.00 |
Volume | 151,400 |
3M AVG Volume | 4.51 |
Today's High | 1,946.00 |
Today's Low | 1,911.00 |
52 Week High | 2,754.00 |
52 Week Low | 1,688.00 |
Shares Out (MIL) | 57.29 |
Market Cap (MIL) | 123,853.40 |
Forward P/E | 16.77 |
Dividend (Yield %) | 3.91 |
Kyorin Holdings Inc - Director Hiromi Watanabe To Become President Effective June 21
Kyorin Holdings to retire treasury shares
Kyorin Holdings to repurchase up to 24.1 pct shares for 44.35 bln yen
KYORIN Holdings, Inc. is a Japan-based holding company mainly engaged in the manufacturing and sales of pharmaceuticals. The Company operates through two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sales of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, as well as the research of new drugs and candidate compounds. It also engages in the purchase and sales of medical promotion tools and packaging materials. The Healthcare segment is engaged in the manufacturing, sales and purchase of environmental sanitation products, general purpose medicines and skin care products.
Industry
Biotechnology & Drugs
Contact Info
15/16F, Ochanomizu Sorashiti
4-6, Kanda Surugadai
+81.3.35254700
http://www.kyorin-gr.co.jpExecutive Leadership
Minoru Hogawa
Chairman of the Board, Chairman of Subsidiary, Representative Director
Yutaka Ogihara
President, Representative Director
Yo Ito
Senior Executive Officer, Senior Director of Group Accounting & Finance
Michio Ohnota
President of Subsidiary, Director
Shigeru Ogihara
Senior Managing Director, President of Subsidiary
Price To Earnings (TTM) | 20.06 |
|---|---|
Price To Sales (TTM) | 1.11 |
Price To Book (MRQ) | 0.92 |
Price To Cash Flow (TTM) | 14.41 |
Total Debt To Equity (MRQ) | 17.29 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | 3.65 |
Return on Equity (TTM) | 3.03 |
* Says its subsidiary KYORIN Rimedio Co., Ltd. has agreed to provide a production and marketing license for generic medicine to BinhDinh Pharmaceutical and Medical Equipment JSC
* Says it will set up a wholly owned drug unit in Tokyo, on Oct. 2
* Says its unit Kyorin Pharmaceutical Co Ltd will acquire 100 percent stake in jTAS Inc
* Says it plans to set up new production subsidiary to take over business from Noshiro plant of unit Kyorin Pharmaceutical Company, Limited and manufacture division of KYORIN Rimedio Co.,Ltd.
* Kyorin Holdings likely will see a 10 percent rise in group operating profit for the year ending in March 2018 - Nikkei
* Says its pharma unit receives license from US firm Merck & Co Inc for drug KRP-114V, a treatment for overactive bladder, owning exclusive rights to develop and commercialize in Asian area
* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I
* Says its unit formed sales business alliance with Air Liquide Japan, Ltd.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.